Stereochemical analysis and biological activity of 3-hydroxy-leukotriene B4

A metabolite from ethanol-treated rat hepatocytes

P. Wheelan, A. Sala, G. Folco, S. Nicosia, J R Falck, R. K. Bhatt, R. C. Murphy

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Leukotriene B4 (LTB4), a biologically active metabolite derived from arachidonic acid by the 5-lipoxygenase cascade, is inactivated by cytochrome P-450-dependent ω-hydroxylation followed by second oxidation into a ω- carboxyl group. In many tissues, this second step is mediated by alcohol dehydrogenase. Isolated rat hepatocytes metabolized LTB4 in the presence of ethanol and ethoxyresorufin into substantial quantities of 3-hydroxy-LTB4 as determined by mass spectrometry. The absolute configuration of this metabolite was found to be greater than 98% 3(S)-hydroxy-LTB4 by comparison to synthetic standards. Investigation of the pharmacologic properties of the 3(S)- and 3(R)-hydroxy-LTB4 revealed that both caused a significant increase in intracellular free calcium in human neutrophils at 1 μM. Both enantiomers also induced thromboxane A2 release from the isolated guinea pig lung in a dose-dependent manner. This activity was fully blocked by a specific LTB4 receptor antagonist, LY223982, with an IC50 of 0.21 μM for LTB4. These results suggested that activation of the LTB4 receptor does not involve significant recognition of the carbon atoms close to the carboxyl moiety of LTB4. The failure of the hepatocyte to metabolically inactivate LTB4 in the presence of ethanol may be of importance to humans, particularly because the bioactive metabolite 3(S)-hydroxy-LTB4 was further metabolized by human neutrophils significantly more slowly than LTB4.

Original languageEnglish (US)
Pages (from-to)1514-1519
Number of pages6
JournalJournal of Pharmacology and Experimental Therapeutics
Volume271
Issue number3
StatePublished - 1994

Fingerprint

Leukotriene B4
Hepatocytes
Ethanol
Leukotriene B4 Receptors
LY 223982
Neutrophils
Leukotriene Antagonists
Arachidonate 5-Lipoxygenase
Thromboxane A2
Alcohol Dehydrogenase
Hydroxylation
Cytochrome P-450 Enzyme System
Inhibitory Concentration 50
Mass Spectrometry
Guinea Pigs
Carbon
Calcium
Lung

ASJC Scopus subject areas

  • Pharmacology

Cite this

Stereochemical analysis and biological activity of 3-hydroxy-leukotriene B4 : A metabolite from ethanol-treated rat hepatocytes. / Wheelan, P.; Sala, A.; Folco, G.; Nicosia, S.; Falck, J R; Bhatt, R. K.; Murphy, R. C.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 271, No. 3, 1994, p. 1514-1519.

Research output: Contribution to journalArticle

@article{b261079c25d74d168dfdf309ae05f445,
title = "Stereochemical analysis and biological activity of 3-hydroxy-leukotriene B4: A metabolite from ethanol-treated rat hepatocytes",
abstract = "Leukotriene B4 (LTB4), a biologically active metabolite derived from arachidonic acid by the 5-lipoxygenase cascade, is inactivated by cytochrome P-450-dependent ω-hydroxylation followed by second oxidation into a ω- carboxyl group. In many tissues, this second step is mediated by alcohol dehydrogenase. Isolated rat hepatocytes metabolized LTB4 in the presence of ethanol and ethoxyresorufin into substantial quantities of 3-hydroxy-LTB4 as determined by mass spectrometry. The absolute configuration of this metabolite was found to be greater than 98{\%} 3(S)-hydroxy-LTB4 by comparison to synthetic standards. Investigation of the pharmacologic properties of the 3(S)- and 3(R)-hydroxy-LTB4 revealed that both caused a significant increase in intracellular free calcium in human neutrophils at 1 μM. Both enantiomers also induced thromboxane A2 release from the isolated guinea pig lung in a dose-dependent manner. This activity was fully blocked by a specific LTB4 receptor antagonist, LY223982, with an IC50 of 0.21 μM for LTB4. These results suggested that activation of the LTB4 receptor does not involve significant recognition of the carbon atoms close to the carboxyl moiety of LTB4. The failure of the hepatocyte to metabolically inactivate LTB4 in the presence of ethanol may be of importance to humans, particularly because the bioactive metabolite 3(S)-hydroxy-LTB4 was further metabolized by human neutrophils significantly more slowly than LTB4.",
author = "P. Wheelan and A. Sala and G. Folco and S. Nicosia and Falck, {J R} and Bhatt, {R. K.} and Murphy, {R. C.}",
year = "1994",
language = "English (US)",
volume = "271",
pages = "1514--1519",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Stereochemical analysis and biological activity of 3-hydroxy-leukotriene B4

T2 - A metabolite from ethanol-treated rat hepatocytes

AU - Wheelan, P.

AU - Sala, A.

AU - Folco, G.

AU - Nicosia, S.

AU - Falck, J R

AU - Bhatt, R. K.

AU - Murphy, R. C.

PY - 1994

Y1 - 1994

N2 - Leukotriene B4 (LTB4), a biologically active metabolite derived from arachidonic acid by the 5-lipoxygenase cascade, is inactivated by cytochrome P-450-dependent ω-hydroxylation followed by second oxidation into a ω- carboxyl group. In many tissues, this second step is mediated by alcohol dehydrogenase. Isolated rat hepatocytes metabolized LTB4 in the presence of ethanol and ethoxyresorufin into substantial quantities of 3-hydroxy-LTB4 as determined by mass spectrometry. The absolute configuration of this metabolite was found to be greater than 98% 3(S)-hydroxy-LTB4 by comparison to synthetic standards. Investigation of the pharmacologic properties of the 3(S)- and 3(R)-hydroxy-LTB4 revealed that both caused a significant increase in intracellular free calcium in human neutrophils at 1 μM. Both enantiomers also induced thromboxane A2 release from the isolated guinea pig lung in a dose-dependent manner. This activity was fully blocked by a specific LTB4 receptor antagonist, LY223982, with an IC50 of 0.21 μM for LTB4. These results suggested that activation of the LTB4 receptor does not involve significant recognition of the carbon atoms close to the carboxyl moiety of LTB4. The failure of the hepatocyte to metabolically inactivate LTB4 in the presence of ethanol may be of importance to humans, particularly because the bioactive metabolite 3(S)-hydroxy-LTB4 was further metabolized by human neutrophils significantly more slowly than LTB4.

AB - Leukotriene B4 (LTB4), a biologically active metabolite derived from arachidonic acid by the 5-lipoxygenase cascade, is inactivated by cytochrome P-450-dependent ω-hydroxylation followed by second oxidation into a ω- carboxyl group. In many tissues, this second step is mediated by alcohol dehydrogenase. Isolated rat hepatocytes metabolized LTB4 in the presence of ethanol and ethoxyresorufin into substantial quantities of 3-hydroxy-LTB4 as determined by mass spectrometry. The absolute configuration of this metabolite was found to be greater than 98% 3(S)-hydroxy-LTB4 by comparison to synthetic standards. Investigation of the pharmacologic properties of the 3(S)- and 3(R)-hydroxy-LTB4 revealed that both caused a significant increase in intracellular free calcium in human neutrophils at 1 μM. Both enantiomers also induced thromboxane A2 release from the isolated guinea pig lung in a dose-dependent manner. This activity was fully blocked by a specific LTB4 receptor antagonist, LY223982, with an IC50 of 0.21 μM for LTB4. These results suggested that activation of the LTB4 receptor does not involve significant recognition of the carbon atoms close to the carboxyl moiety of LTB4. The failure of the hepatocyte to metabolically inactivate LTB4 in the presence of ethanol may be of importance to humans, particularly because the bioactive metabolite 3(S)-hydroxy-LTB4 was further metabolized by human neutrophils significantly more slowly than LTB4.

UR - http://www.scopus.com/inward/record.url?scp=0028148412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028148412&partnerID=8YFLogxK

M3 - Article

VL - 271

SP - 1514

EP - 1519

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -